109 related articles for article (PubMed ID: 23319309)
1. In vitro activities of levofloxacin, gatifloxacin, moxifloxacin and garenoxacin against Bacteroides fragilis strains evaluated by kill kinetics.
Schaumann R; Janssen E; Funke M; Stîngu CS; Genzel GH; Janssen M; Rodloff AC
J Med Microbiol; 2013 Apr; 62(Pt 4):576-581. PubMed ID: 23319309
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
3. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Ricci V; Piddock L
J Antimicrob Chemother; 2003 Oct; 52(4):605-9. PubMed ID: 12951329
[TBL] [Abstract][Full Text] [Related]
5. Differences in distribution and antimicrobial susceptibility of anaerobes isolated from complicated intra-abdominal infections versus diabetic foot infections.
Claros M; Citron DM; Goldstein EJ; Merriam CV; Tyrrell KL
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):546-8. PubMed ID: 23727512
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of garenoxacin tested by kill-curve methodology against wild type and QRDR mutant strains of Streptococcus pneumoniae.
Anderegg TR; Jones RN
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):213-7. PubMed ID: 15541608
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
[TBL] [Abstract][Full Text] [Related]
8. In vitro pharmacodynamic evaluation of garenoxacin against quinolone-resistant Streptococcus pneumoniae.
Fukuda Y; Takahata M; Sugiura Y; Shinmura Y; Nomura N
Int J Antimicrob Agents; 2012 Feb; 39(2):163-7. PubMed ID: 22088660
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
Goldstein EJ; Solomkin JS; Citron DM; Alder JD
Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
[TBL] [Abstract][Full Text] [Related]
10. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
11. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
[TBL] [Abstract][Full Text] [Related]
12. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Waites KB; Crabb DM; Bing X; Duffy LB
Antimicrob Agents Chemother; 2003 Jan; 47(1):161-5. PubMed ID: 12499185
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.
Peterson ML; Hovde LB; Wright DH; Brown GH; Hoang AD; Rotschafer JC
Antimicrob Agents Chemother; 2002 Jan; 46(1):203-10. PubMed ID: 11751135
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
Noviello S; Ianniello F; Leone S; Esposito S
J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
[TBL] [Abstract][Full Text] [Related]
16. [Can meropenem E-test be used to estimate the presence of carbapenem resistance gene cfiA among Bacteroides fragilis strains?].
Toprak Ülger N; Ilki A; Ozel N; Balkan N; Söyletir G
Mikrobiyol Bul; 2011 Jul; 45(3):385-91. PubMed ID: 21935771
[TBL] [Abstract][Full Text] [Related]
17. Development of EUCAST disk diffusion method for susceptibility testing of the Bacteroides fragilis group isolates.
Nagy E; Justesen US; Eitel Z; Urbán E;
Anaerobe; 2015 Feb; 31():65-71. PubMed ID: 25464140
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the new quinolone WCK 771 against staphylococci.
Jacobs MR; Bajaksouzian S; Windau A; Appelbaum PC; Patel MV; Gupte SV; Bhagwat SS; De Souza NJ; Khorakiwala HF
Antimicrob Agents Chemother; 2004 Sep; 48(9):3338-42. PubMed ID: 15328094
[TBL] [Abstract][Full Text] [Related]
19. Inducible metronidazole resistance in nim-positive and nim-negative bacteroides fragilis group strains after several passages metronidazole containing columbia agar plates.
Schaumann R; Petzold S; Fille M; Rodloff AC
Infection; 2005 Oct; 33(5-6):368-72. PubMed ID: 16258869
[TBL] [Abstract][Full Text] [Related]
20. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
